modelJ05AB06_2
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Ganciclovir_2 | |
| ATC code: | J05AB06_2 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 0.69 | L |
| clearance: | 4.6 | mL/min/kg |
| other parameters in model implementation | ||
Ganciclovir is an antiviral medication used mainly to prevent and treat cytomegalovirus (CMV) infections, notably in immunocompromised individuals, such as those with HIV/AIDS, organ transplant, or undergoing chemotherapy.
Pharmacokinetics
Following oral administration (as valganciclovir, ganciclovir prodrug), healthy adults.
References
Nguyen, T, et al., & Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02254-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318012
Perrottet, N, et al., & Buclin, T (2009). Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrobial agents and chemotherapy 53(7) 3017–3023. DOI:10.1128/AAC.00836-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19307355
Caldés, A, et al., & Grinyó, JM (2009). Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrobial agents and chemotherapy 53(11) 4816–4824. DOI:10.1128/AAC.00085-09 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19738014
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)